Biological Dynamics CEO Dr. Paul Billings was interviewed in a recent interview for the San Diego Union Tribune, discussing the history and future of the company as it moves to early stage trials for pancreatic cancer detection. Read the article here.
Biological Dynamics today announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics’ proprietary technology to benefit their new company, EXOKĒRYX, Inc.
Read MoreBiological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today that its Director of Medical Affairs, Harmeet Dhani, MD, MSc, will speak at the inaugural PRECEDE Early Detection Biomarker Summit in New York.
Read MoreBiological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today it has received IRB approval and will soon begin to enroll patients in its ExoLuminate™ clinical study to validate its pancreatic ductal adenocarcinoma (PDAC) lab-developed test (LDT).
Read MoreBiological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics.
Read MoreDiagnostics industry veterans Mike Aicher, Mike Nall, and Mike Russell have joined Biological Dynamics.
Read MoreBiological Dynamics, Inc. announces participation in a series of global events to discuss liquid biopsy industry trends and challenges, and to review new early-stage cancer detection data based on our company’s proprietary platform technology. Events include:
April 5, 2022: Chief Medical Officer Summit 360 – Fireside Chat with Dr. Paul Billings, CEO and Director
April 8 – 13, 2022: AACR (American Association for Cancer Research) Annual Meeting – Lung cancer and Pancreatic cancer data
May 16, 2022: AUA (American Urological Association) Annual Meeting – Bladder cancer data
May 25 – 29, 2022: ISEV (International Society for Extracellular Vesicles) Annual Meeting – Pancreatic, Ovarian, and Bladder cancer data
June 21, 2022: Nephron Liquid Biopsy Innovation Symposium
June 30, 2022: PMWC (Precision Medicine World Conference) – Early-stage cancer data
Biological Dynamics, Inc. announces the publication of its study, Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test, published in Nature Communications Medicine. The test correctly identified 71 percent of stage 1 cancers in a combined cohort of pancreatic, ovarian, and bladder cancers with pancreatic stage 1 cancer detection at 96%.
“The results are remarkable and highlight exosomal protein markers as a viable candidate for early-stage cancer detection,” said Scott Lippman, M.D., co-senior author of this report and Director of UC San Diego Moores Cancer Center. “Specifically, pancreatic cancer is notoriously difficult to detect at an early stage, when surgery, the only curative therapy, is possible. Biological Dynamics’ assay is demonstrating the potential for early-stage cancer detection to be included in the standard of care."
Read MoreBiological Dynamics, Inc., a novel multiomic test company focused on detecting diseases at their earliest stages, announced the return of Paul Billings, MD, PhD, FACP, FACMGG to the company as Chief Executive Officer and Director. Previously, Dr. Billings has served in Advisor, Director, and Board Chairman roles before leaving to become Chief Medical Officer and Senior Vice President of Medical Affairs at Natera, Inc.
Read MoreBiological Dynamics, Inc., a multiomics liquid biopsy company focused on detecting cancers at the earliest stages, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its liquid biopsy assay, Exo-PDAC. The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.
Read MoreBiological Dynamics, Inc., a next-generation liquid biopsy company focused on detecting cancers at the earliest stages, will present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California. The panel discussion takes place on Tuesday, August 10, 2021 at 7:00 p.m. PT.
Kevin Han, CFO, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Emerging Players in Liquid Biopsy, focused on Biological Dynamics’ patented technology that empowers cancer detection at the earliest stages.
Read MoreCEO Raj Krishnan, Ph.D. and CFO Kevin Han, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Novel Approaches for Early Cancer Detection, on Wednesday, June 16, 2021, at 12:10 p.m. ET / 9:10 a.m. PT.
Biological Dynamics will discuss a transformative approach to cancer screening using a proprietary platform that enables the isolation and evaluation of non-DNA biomarkers, such as exosomes, exo-proteins, and surfaceomes. The company will also discuss how the access to these differentiated biomarkers from blood can empower cancer detection at the earliest stages.
Read MoreBiological Dynamics, Inc., a healthcare company committed to improving global health outcomes by detecting diseases at an early stage, will present at the 39th Annual J.P. Morgan Healthcare Conference. CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will provide an overview of the company and host a Q&A on Tuesday, January 12, 2021, at 5:30 p.m. ET.
Read MoreBiological Dynamics announced it has named Kevin Han as its new Chief Financial Officer, bringing a depth of expertise in capital markets and investor relations and a breadth of healthcare industry knowledge. Mr. Han, a veteran life science industry investor, joins Biological Dynamics following an accomplished career in equity research, investment management, and investor relations, specifically focused on the life science tools, diagnostics, and medical technology sectors.
Read MoreBiological Dynamics, Inc., an innovative diagnostic company committed to improving global health, today announced a supplemental grant to support efforts to optimize and evaluate the performance of a novel TB test currently in development. The funding is from the Bill & Melinda Gates Foundation.
Read MoreBiological Dynamics, Inc., an innovative diagnostic company committed to improving global health, today announced it has been accepted to Microsoft's One Commercial Partner (OCP) program. The company will use the comprehensive development solutions available to OCP partners to develop and establish a research service delivery model, to provide Microsoft's Life Science partners and customers access to cutting edge molecular diagnostic solutions powered by Biological Dynamics' novel isolation platform.
Read MoreBiological Dynamics, Inc., an innovative diagnostic company committed to improving global health outcomes, today announced a new grant award from the Bill & Melinda Gates Foundation.
Read MoreSAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, a company committed to improving global health outcomes by empowering global communities with accessible cancer diagnostics, today announced that its OmniVerita™ system has been selected as the winner of CONNECT’s Most Innovative New Product Award in the Life Science Products, Clinical Stage category.
Read MoreSAN DIEGO--(BUSINESS WIRE)--Today, Biological Dynamics announced it has received a grant from the Bill & Melinda Gates Foundation to help address the pressing need of reducing the burden of tuberculosis (TB) in resource-poor settings.
Read MoreSan Diego, Calif. —April 13, 2018— Biological Dynamics, a company committed to improving global health outcomes by empowering global communities with low-cost, accessible cancer diagnostics, today announced two additions to its Board of Directors. Irwin Jacobs, founding Chairman and CEO Emeritus of Qualcomm and Chairman Emeritus of the Salk Institute for Biological Studies, and Martin J. Wygod, the founder of Medco Containment Services Inc. and former Chairman of WebMD Health Corp., have joined Biological Dynamics’ Board of Directors.
Read MoreBiological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.
